.webp)
67/100BRoyalty Pharma stock buybacks 2017–2026What are stock buybacks? A stock buyback is a company buying its own shares on the market. With fewer shares left, each remaining share owns a bigger part of the company.
Royalty Pharma spent 86.34M USD buying back its shares in Q3 FY2026, the three months to 30 September 2026, down 41.1% on the same quarter a year before. Royalty Pharma spent 261.62M USD buying back its shares over the last twelve months, down 78.2% on the twelve months before. In fiscal year 2025 it spent 1.23B USD, up 434.5% on the year before.
Last updated 6 Nov 2026 · Next report 10 Feb 2027
Stock buybacks
Growth
| Fiscal year | Period ending | Stock buybacks | Growth | Dividends paid | Free cash flow |
|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | 261.62M | -78.19% | 408.87M | 2.96B |
| FY2025 | 31 Dec 2025 | 1.23B | +434.46% | 378.25M | 2.49B |
| FY2024 | 31 Dec 2024 | 229.65M | -24.65% | 376.47M | 2.77B |
| FY2023 | 31 Dec 2023 | 304.76M | — | 358.33M | 2.99B |
| FY2022 | 31 Dec 2022 | 0.00 | — | 333.32M | 2.14B |
| FY2021 | 31 Dec 2021 | 0.00 | — | 285.18M | 2.02B |
| FY2020 | 31 Dec 2020 | 0.00 | -100.00% | 397.84M | 2.03B |
| FY2019 | 31 Dec 2019 | 4.27M | — | 739.28M | 1.67B |
| FY2018 | 31 Dec 2018 | 0.00 | — | 814.36M | 1.62B |
| FY2017 | 31 Dec 2017 | 0.00 | — | 735.17M | 1.42B |
| Quarter | Period ending | Stock buybacks | Growth on a year before | Dividends paid | Free cash flow |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 86.34M | -41.06% | 105.12M | 686.08M |
| Q2 FY2026 | 30 Jun 2026 | 44.64M | -84.69% | 104.92M | 686.16M |
| Q1 FY2026 | 31 Mar 2026 | 50.10M | -92.93% | 104.49M | 760.54M |
| Q4 FY2025 | 31 Dec 2025 | 80.54M | +53.09% | 94.34M | 827.15M |
| Q3 FY2025 | 30 Sept 2025 | 146.49M | +50.95% | 95.31M | 702.62M |
| Q2 FY2025 | 30 Jun 2025 | 291.57M | +264.47% | 93.24M | 363.98M |
| Q1 FY2025 | 31 Mar 2025 | 708.78M | — | 95.36M | 596.08M |
| Q4 FY2024 | 31 Dec 2024 | 52.61M | +74.20% | 93.66M | 742.53M |
| Q3 FY2024 | 30 Sept 2024 | 97.05M | -30.74% | 94.06M | 703.61M |
| Q2 FY2024 | 30 Jun 2024 | 80.00M | — | 94.94M | 658.21M |
| Q1 FY2024 | 31 Mar 2024 | 0.00 | — | 93.81M | 664.64M |
| Q4 FY2023 | 31 Dec 2023 | 30.20M | — | 89.34M | 772.63M |
| Q3 FY2023 | 30 Sept 2023 | 140.12M | — | 89.75M | 573.52M |
| Q2 FY2023 | 30 Jun 2023 | 0.00 | — | 90.61M | 607.82M |
| Q1 FY2023 | 31 Mar 2023 | 0.00 | — | 88.63M | 1.03B |
| Q4 FY2022 | 31 Dec 2022 | 0.00 | — | 84.20M | 569.93M |
| Q3 FY2022 | 30 Sept 2022 | 0.00 | — | 83.81M | 538.83M |
| Q2 FY2022 | 30 Jun 2022 | 0.00 | — | 83.05M | 574.95M |
| Q1 FY2022 | 31 Mar 2022 | 0.00 | — | 82.26M | 460.27M |
| Q4 FY2021 | 31 Dec 2021 | 0.00 | — | 73.60M | 489.96M |
| Q3 FY2021 | 30 Sept 2021 | 0.00 | — | 73.02M | 469.76M |
| Q2 FY2021 | 30 Jun 2021 | 0.00 | — | 72.58M | 531.72M |
| Q1 FY2021 | 31 Mar 2021 | 0.00 | — | 65.98M | 526.10M |
| Q4 FY2020 | 31 Dec 2020 | 0.00 | — | 57.61M | 565.67M |
| Q3 FY2020 | 30 Sept 2020 | 0.00 | — | 54.88M | 508.85M |
| Q2 FY2020 | 30 Jun 2020 | 0.00 | -100.00% | 143.58M | 489.00M |
| Q1 FY2020 | 31 Mar 2020 | 0.00 | -100.00% | 141.78M | 471.10M |
| Q4 FY2019 | 31 Dec 2019 | 0.00 | — | 175.24M | 478.43M |
| Q3 FY2019 | 30 Sept 2019 | 0.00 | — | 167.99M | 419.03M |
| Q2 FY2019 | 30 Jun 2019 | 1.90M | — | 198.38M | 336.79M |
| Q1 FY2019 | 31 Mar 2019 | 2.33M | — | 197.67M | 432.99M |
Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
The money spent buying back the company's own shares in each period, from the cash flow statement.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow
Common questions about Royalty Pharma's buybacks
Source: Financial Modeling Prep